Compare iShares MSCI Taiwan ETF (EWT) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Taiwan ETF vs Sanofi SA — how do they compare? iShares MSCI Taiwan ETF trades at $100.01, while Sanofi SA trades at $44.16 (market cap $103.94B). The key difference: Sanofi SA pays a 5.54% dividend while iShares MSCI Taiwan ETF pays none, and iShares MSCI Taiwan ETF is trading nearer its 52-week high, Sanofi SA nearer its low. Which is the better fit depends on your goals.
| EWT | SNY | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $111.53 | $52.34 |
52-Week Low | $58.05 | $41.33 |
Market Cap | — | $103.94B |
Enterprise Value | — | $120.43B |
Dividend Yield | — | 5.54% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWT (iShares MSCI Taiwan ETF) trades at $100.60, down 1.26% on the day amid neutral technical signals. The ETF has delivered exceptional performance with a 100%+ gain in 2026, driven by Taiwan's dominant semiconductor sector and AI infrastructure exposure. Current technical indicators show mixed signals with bullish moving averages but neutral oscillators, while support levels cluster around $99-$101.
The outlook remains favorable given Taiwan's critical role in global semiconductor supply chains and AI infrastructure growth, though stretched valuations and geopolitical tensions with China present significant risks. Institutional interest remains strong due to concentrated exposure to TSMC and other tech leaders, but investors should monitor dollar movements and regional stability.
Sanofi (SNY) trades at $44.11, up 2.15% today, with a bullish technical signal supported by moving averages. The company shows strong fundamentals with a P/E of 19.37, net income margin of 15.95%, and consistent earnings beats in recent quarters. Recent FDA approval for Sarclisa's subcutaneous formulation and EU clearance for Cenrifki highlight pipeline progress, while a dividend of $2.42 per share underscores shareholder returns.
Outlook remains positive driven by Dupixent growth and new drug approvals, though risks include EU antitrust probes and competitive pressures. Analysts are mixed with 44% buy ratings, suggesting cautious optimism. The stock presents value with solid cash flow and profitability, but investors should monitor regulatory developments and pipeline execution for sustained upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI Taiwan ETF
EWT tracks the MSCI Taiwan 25/50 Index, providing targeted exposure to large and mid-cap companies in Taiwan. It is heavily concentrated in the information technology sector, serving as a liquid instrument for investors seeking a single-country view of Taiwan's export-oriented and tech-driven economy.
Read more on EWT →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
